Sugi Predict

Sugi Predict / Compounds / SCHEMBL309397

SCHEMBL309397

SCHEMBL309397

OB(O)c1ccc(F)c(O)c1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CA3 P07451 1/20 0.52
▸ CA6 P23280 1/20 0.52
▸ CA5A P35218 1/20 0.52
▸ CA9 Q16790 1/20 0.52
▸ CA14 Q9ULX7 1/20 0.52
▸ CA5B Q9Y2D0 1/20 0.52
▸ ENPP2 Q13822 4/20 0.44
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ HSD17B1 P14061 3/20 0.39
▸ HSD17B2 P37059 3/20 0.39
▸ MGLL Q99685 2/20 0.38
▸ TTR P02766 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954381 1.00 CA3 (0.52) CA3CA6CA5ACA9CA14
SCHEMBL423468 0.81 ENPP2 (0.44) ENPP2CA1CA2HSD17B1HSD17B2
SCHEMBL128893 0.80 ENPP2 (0.46) ENPP2CA1CA2MGLLTTR
SCHEMBL28490899 0.78 ENPP2 (0.44) ENPP2CA1CA2MGLLTTR
SCHEMBL1277359 0.77 ENPP2 (0.50) ENPP2CA1CA2TTR
SCHEMBL22207451 0.76 ENPP2 (0.42) ENPP2CA1CA2MGLLTTR
SCHEMBL15573811 0.74 CA2 (0.46) ENPP2CA1CA2MGLLTTR
SCHEMBL31333 0.74 TTR (0.55) ENPP2CA1CA2TTR
SCHEMBL177567 0.74 CA2 (0.46) ENPP2CA1CA2MGLLTTR
SCHEMBL29427024 0.74 CA2 (0.46) ENPP2CA1CA2MGLLTTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116731315-B Boron-containing phthalonitrile resin and preparation method and application thereof 中国科学院化学研究所 2024-06-21 — — CN claimed
CN-116731315-A Boron-containing phthalonitrile resin and preparation method and application thereof 中国科学院化学研究所 2023-09-12 — — CN claimed
CN-111146496-B Polymer electrolyte and lithium ion battery containing same 珠海冠宇电池股份有限公司 2021-07-13 — — CN claimed
CN-111146496-A Polymer electrolyte and lithium ion battery containing same 珠海冠宇电池有限公司 2020-05-12 — — CN claimed
US-20260132123-A1 ABAD INHIBITOR COMPOUNDS UNIV COURT OF THE UNIV OF ST ANDREWS (GB) 2026-05-14 — — US disclosed
WO-2026090477-A1 HELICASE INHIBITORS AND USES THEREOF KIMIA THERAPEUTICS, INC. (US) 2026-04-30 — — WO disclosed
US-12595273-B2 Phosphonate conjugates and uses thereof TRANSLATIONAL GENOMICS RES INST (US) 2026-04-07 — — US disclosed
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 — — US disclosed
EP-4635494-A2 AMIDO HETEROAROMATIC COMPOUNDS Astrazeneca AB (SE) 2025-10-22 — — EP disclosed
EP-4514782-B1 AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES ASTRAZENECA AB (SE) 2025-09-10 — — EP disclosed
US-12291524-B2 Amido heteroaromatic compounds ASTRAZENECA AB (SE) 2025-05-06 — — US disclosed
US-12258323-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2025-03-25 — — US disclosed
EP-2234995-A1 LEUKOTRIENE B4 INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-10-06 — — EP disclosed
US-20090253684-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-10-08 — — US disclosed
WO-2009109483-A1 LEUKOTRIENE B4 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 — — WO disclosed
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-09-10 — — US disclosed
WO-2009077385-A1 LEUKOTRIENE B4 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 — — WO disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 — — US disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 — — US disclosed
WO-2008153858-A1 POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER SCHERING CORPORATION (US) 2008-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12291524-B2 Amido heteroaromatic compounds CYP7A1, SLC10A1, CYP11B2 CA3 4519/4885CA6 2501/4885CA5A 1537/4885
US-20090253684-A1 LEUKOTRIENE B4 INHIBITORS LTB4R2, LTB4R, LTC4S CA3 4778/4885CA6 3730/4885CA5A 2232/4885
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS LTB4R2, LTB4R, LTC4S CA3 4793/4885CA6 3710/4885CA5A 2226/4885
US-20090118284-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPK10 CA3 4826/4885CA6 4604/4885CA5A 4070/4885
US-20260132123-A1 ABAD INHIBITOR COMPOUNDS ADH1C, ADH1A, CBR1 CA3 431/4885CA6 485/4885CA5A 508/4885
US-12258323-B2 Dihydrooxadiazinones CCND2, CCNT2, CCND1 CA3 4817/4885CA6 4397/4885CA5A 2112/4885
US-12595273-B2 Phosphonate conjugates and uses thereof RET, PTK2, ERBB2 CA3 3051/4885CA6 1628/4885CA5A 1988/4885
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A CA3 4632/4885CA6 4462/4885CA5A 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.